Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI 3-1 Month Momentum % is -16.34% as of Jul. 28, 2026. Among 1,030 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 62.23% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-28), Petros Pharmaceuticals's 3-1 Month Momentum % is -16.34%.
The industry rank for Petros Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
PTPI's 3-1 Month Momentum % is ranked worse than 62.23% of 1030
companies
in the Drug Manufacturers industry
Industry Median: -10.32
vs PTPI: -16.34
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Petros Pharmaceuticals 3-1 Month Momentum % Related Terms
PTPI vs KOAN, KAYS, OWPC: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a 3-1 Month Momentum % of -16.34% as of Jul. 28, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #641 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 62.2%.
Is Petros Pharmaceuticals' 3-1 Month Momentum % too high?
Petros Pharmaceuticals' current 3-1 Month Momentum % is -16.34%. Based on the distribution chart, Petros Pharmaceuticals ranks #641 out of 1030 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Petros Pharmaceuticals' 3-1 Month Momentum % compare to KOAN and KAYS?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #641 out of 1030 companies for 3-1 Month Momentum %. This places Petros Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Petros Pharmaceuticals and its competitors. Petros Pharmaceuticals's current 3-1 Month Momentum % is -16.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current 3-1 Month Momentum % of -16.34%. The current 3-1 Month Momentum % is -16.34%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current 3-1 Month Momentum % is -16.34% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
